ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "The doxycycline paradox in mitochondrial disease"
Episode Synopsis
Expanding on their recent editorial, Shamima Rahman, Eva Morava and Tamas Kozicz discuss the doxycycline paradox and why a medication previously thought to be toxic might present an avenue for treatment in some primary mitochondrial disorders.
The doxycycline paradox in primary mitochondrial diseases
Tamas Kozicz, Shamima Rahman, and Eva Morava
https://doi.org/10.1002/jimd.12531
The doxycycline paradox in primary mitochondrial diseases
Tamas Kozicz, Shamima Rahman, and Eva Morava
https://doi.org/10.1002/jimd.12531
More episodes of the podcast JIMD Podcasts
Shortcast: Liver Directed Rx don’t change biochemistry nor Leukodystrophy in Biallelic HMBS Variants
30/12/2025
Sixty Years of Metabolic Medicine: A Conversation with Jean-Marie Saudubray and Manuel Schiff
23/12/2025
Shortcast: Exploratory Study on the Challenges of Newborn Screening for Lysosomal Storage Disorders
25/11/2025
IMD Research Round-Up: Mitochondrial disease
11/11/2025
In God we trust